GTBP GT Biopharma, Inc.

Nasdaq gtbiopharma.com


$ 0.67 $ 0.00 (0 %)    

Wednesday, 19-Nov-2025 04:37:02 EST
QQQ $ 598.23 $ 0.00 (0 %)
DIA $ 461.70 $ 0.00 (0 %)
SPY $ 662.00 $ 0.00 (0 %)
TLT $ 89.00 $ 0.00 (0 %)
GLD $ 377.46 $ 0.00 (0 %)
$ 0.6555
$ 0.67
$ 0.66 x 2,999
$ 0.67 x 886
-- - --
$ 0.54 - $ 4.10
774,928
na
6.97M
$ 1.24
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-14-2025 09-30-2025 10-Q
2 08-14-2025 06-30-2025 10-Q
3 05-15-2025 03-31-2025 10-Q
4 02-21-2025 12-31-2024 10-K
5 11-14-2024 09-30-2024 10-Q
6 08-14-2024 06-30-2024 10-Q
7 05-15-2024 03-31-2024 10-Q
8 03-26-2024 12-31-2023 10-K
9 11-01-2023 09-30-2023 10-Q
10 08-07-2023 06-30-2023 10-Q
11 05-15-2023 03-31-2023 10-Q
12 03-30-2023 12-31-2022 10-K
13 10-31-2022 09-30-2022 10-Q
14 08-15-2022 06-30-2022 10-Q
15 05-16-2022 03-31-2022 10-Q
16 03-28-2022 12-31-2021 10-K
17 11-10-2021 09-30-2021 10-Q
18 08-23-2021 06-30-2021 10-Q
19 05-17-2021 03-31-2021 10-Q
20 04-16-2021 12-31-2020 10-K
21 11-13-2020 09-30-2020 10-Q
22 08-14-2020 06-30-2020 10-Q
23 05-15-2020 03-31-2020 10-Q
24 03-27-2020 12-31-2019 10-K
25 11-14-2019 09-30-2019 10-Q
26 08-14-2019 06-30-2019 10-Q
27 05-15-2019 03-31-2019 10-Q
28 03-29-2019 12-31-2018 10-K
29 11-14-2018 09-30-2018 10-Q
30 08-14-2018 06-30-2018 10-Q
31 05-15-2018 03-31-2018 10-Q
32 03-01-2018 12-31-2017 10-K
33 11-14-2017 09-30-2017 10-Q
34 08-11-2017 06-30-2017 10-Q
35 04-28-2017 03-31-2017 10-Q
36 03-31-2017 12-31-2016 10-K
37 11-14-2016 09-30-2016 10-Q
38 08-10-2016 06-30-2016 10-Q
39 05-13-2016 03-31-2016 10-Q
40 03-30-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 gt-biopharma-q2-eps-055-beats-068-estimate

GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.68) ...

 gt-biopharma-initiated-dosing-in-cohort-3-of-its-phase-1-dose-escalation-trial-of-gtb-3650-for-relapsed-or-refractory-cd33-expressing-hematologic-malignancies-plans-on-releasing-initial-phase-1-results-later-in-2025-following-completion-of-additional-dose-cohorts

The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful...

 gt-biopharma-q1-eps-033-beats-064-estimate

GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.64) ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION